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Medulloblastoma, one of the most malignant brain tumors in children, is thought to arise from undiffer-
entiated neural stem/progenitor cells (NSCs) present in the external granule layer of the cerebellum. However,
the mechanism of tumorigenesis remains unknown for the majority of medulloblastomas. In this study, we
found that many human medulloblastomas express significantly elevated levels of both myc oncogenes, regu-
lators of neural progenitor proliferation, and REST/NRSF, a transcriptional repressor of neuronal differen-
tiation genes. Previous studies have shown that neither c-Myc nor REST/NRSF alone could cause tumor
formation. To determine whether c-Myc and REST/NRSF act together to cause medulloblastomas, we used a
previously established cell line derived from external granule layer stem cells transduced with activated c-myc
(NSC-M). These immortalized NSCs were able to differentiate into neurons in vitro. In contrast, when the cells
were engineered to express a doxycycline-regulated REST/NRSF transgene (NSC-M-R), they no longer under-
went terminal neuronal differentiation in vitro. When injected into intracranial locations in mice, the NSC-M
cells did not form tumors either in the cerebellum or in the cerebral cortex. In contrast, the NSC-M-R cells did
produce tumors in the cerebellum, the site of human medulloblastoma formation, but not when injected into
the cerebral cortex. Furthermore, the NSC-M-R tumors were blocked from terminal neuronal differentiation.
In addition, countering REST/NRSF function blocked the tumorigenic potential of NSC-M-R cells. To our
knowledge, this is the first study in which abnormal expression of a sequence-specific DNA-binding transcrip-
tional repressor has been shown to contribute directly to brain tumor formation. Our findings indicate that
abnormal expression of REST/NRSF andMyc in NSCs causes cerebellum-specific tumors by blocking neuronal
differentiation and thus maintaining the “stemness” of these cells. Furthermore, these results suggest that
such a mechanism plays a role in the formation of human medulloblastoma.
Most medulloblastomas are believed to originate from un-
differentiated neural stem/progenitor cells (NSCs) present in
the external granule layer cells of the cerebellum (15, 18, 22,
41, 50). The primitive “embryonal” appearance of medullo-
blastoma cells, as well as their capacity for divergent differen-
tiation, has led to the suggestion that they have a neural stem
cell-like phenotype (18, 22). In addition to arising from stem
cells, human medulloblastomas appear to contain stem-like
cells required for tumor propagation (59). Induction of neu-
ronal and glial markers in medulloblastoma cells has been
documented as a response to several proposed chemothera-
peutic agents (6, 42, 64), supporting the hypothesis that these
tumors show lack of terminal differentiation and suggesting
regulation of differentiation status as a promising treatment
avenue.
Pathways regulating cerebellar development, such as Hedge-
hog and Wnt, have been found to be activated by genetic
alterations during medulloblastoma tumorigenesis (15, 21, 44,
50, 66, 68, 69). Both Hedgehog and Wnt are thought to regu-
late proliferation and differentiation of neural stem cells and
may play a similar role in medulloblastoma. However, muta-
tions activating these pathways have been documented in only
a modest percentage of human tumors. The receptor gene
PTCH is the member of the Hedgehog pathway most com-
monly altered in medulloblastoma, but sensitive techniques
such as direct sequencing have identified mutations in no more
than 10% of cases (14). Similarly, mutations in CTNNB1 and
Axin activating the Wnt pathway have been identified in less
than 20% of sporadic medulloblastomas (13, 32, 70). Thus, the
mechanism of tumorigenesis for the majority of medulloblas-
tomas is still unknown.
The Myc oncoproteins are also important in medulloblas-
toma pathogenesis (1, 7, 26). c-myc and N-myc are commonly
amplified in the biologically aggressive large cell/anaplastic
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medulloblastoma subtype (17, 40). In addition, overexpression
of c-Myc mRNA due to gene amplification or other unidenti-
fied mechanisms has been associated with worse clinical out-
comes (15, 16, 24, 26). N-Myc also has been implicated in the
development of medulloblastoma as a result of Shh pathway
activation (30, 39, 51, 54). However, the c-Myc oncoprotein, or
its activated form, v-Myc, is insufficient to cause medulloblas-
toma when acting alone in NSCs (20, 38, 52, 55, 60).
REST/NRSF is a global transcriptional repressor that con-
tains a DNA binding domain and two repressor domains; it
silences the transcription of a large number of neuronal dif-
ferentiation genes by binding to a 23-bp consensus DNA se-
quence, the RE1 binding site/neuron restrictive silencer (RE1/
NRSE), present in these genes’ regulatory regions (3, 4, 8, 12).
REST/NRSF is mostly expressed in embryonic stem cells and
nonneuronal cells and is rarely expressed in neurons in vivo (3,
4). However, REST/NRSF is expressed in certain mature neu-
rons in adults (23, 33, 56), suggesting that it has a complex role
that depends on its cellular and physiological environment.
Furthermore, there are several isoforms of REST/NRSF, and
one such isoform, REST4, functions as a dominant-negative
regulator by interfering with REST/NRSF’s activity in neurons
(56, 58). Both REST/NRSF and REST4 interact with RILP, a
LIM domain protein, for nuclear translocation (56, 57). For
REST/NRSF-dependent promoter repression to occur, REST/
NRSF must interact with several cellular cofactors, including
Co-REST, N-CoR, mSin3A, and the histone deacetylase com-
plex, and modulate chromatin structure (2–5, 12, 23, 29). Fur-
thermore, a small, double-stranded RNA has been found to
modulate REST/NRSF activity in the NSCs as well (34). Our
previous work showed that several medulloblastoma cell lines
and many human medulloblastomas overexpress REST/NRSF
compared with neuronal progenitor cells and fully differenti-
ated neurons (19, 37). However, neuronal cells constitutively
expressing REST/NRSF do not form into tumors and appear
to acquire a normal neuronal morphology, except that they
manifest axon pathfinding errors (49). Similarly, our transgenic
mice expressing REST/NRSF in neuronal cells appeared to
develop normally without tumor formation (unpublished
data).
To study what happens when the effects of REST/NRSF are
opposed, we constructed a recombinant transcription factor,
REST-VP16, in which both the repressor domains of REST/
NRSF were replaced with the activation domain of the herpes
simplex virus protein VP16 (28, 37, 63, 65). We found that
REST-VP16 operates through RE1/NRSE, competes with en-
dogenous REST/NRSF for DNA binding, and activates cellu-
lar REST/NRSF target genes. Furthermore, the high-efficiency
expression of REST-VP16 mediated by the adenovirus con-
struct Ad.REST-VP16 in human medulloblastoma cells coun-
tered the endogenous REST/NRSF-mediated repression of
neuronal promoters and promoted apoptosis through caspase
3 activation, presumably resulting from the simultaneous op-
posing action of REST/NRSF and REST-VP16 (19, 37). Be-
cause it leads to apoptosis, REST-VP16 also blocks the tumor-
igenicity of medulloblastoma cells (19, 37).
The experiments described here indicate that abnormal ex-
pression of REST and Myc in NSCs cooperate to form cere-
bellar tumors by blocking neuronal differentiation. Although
the role of naturally occurring, DNA-binding transcriptional
activators in oncogenesis is well established, the role of tran-
scriptional repressors is not. Currently, there is only indirect
evidence linking repressors such as evi-1 and CtBP to onco-
genesis; a strong link of these repressors with their in vivo gene
targets is lacking (9, 10). The study here also describes such a
direct role of a transcriptional repressor in forming medullo-
blastoma by blocking neuronal differentiation.
MATERIALS AND METHODS
Histological and immunohistochemical assays. For the histological studies, 21
surgically excised human brain tumor tissue and adjacent normal tissue samples
fixed in 10% buffered formalin and embedded in paraffin were obtained from the
Brain Tumor Center tissue bank at The University of Texas M. D. Anderson
Cancer Center, stained with hematoxylin and eosin (H&E), and examined under
a light microscope, as previously described (19, 65). These experiments were
done with institutional review board approval. All specimens had been previously
determined to be medulloblastomas on the basis of histological findings. Six
normal cerebellar tissue samples adjacent to tumors, which were histopatholog-
ically distinct from the tumor tissue, were included in the array as negative
controls. For the immunohistochemical assays, the brain sections were stained
with an anti-REST antibody (a gift of Gail Mandel), an anti-c-Myc antibody
(Santa Cruz), and an anti-N-Myc antibody (Santa Cruz), and this was done
essentially as previously described (19, 22, 65). The staining intensity was graded
as negative (), weakly positive (), or strongly positive () and was deter-
mined on the basis of the staining intensity of 15 to 20 representative fields from
each section.
Real-time RT-PCR. Real-time reverse transcription-PCR (RT-PCR) was per-
formed as follows. Medulloblastoma samples were obtained from The Johns
Hopkins Hospital and were snap frozen at the time of resection. Diagnoses were
confirmed by a neuropathologist (C.G.E.). These studies were approved by the
local institutional review board. Total RNA was prepared using QIAGEN RNA-
Easy tissue kits according to the manufacturer’s instructions (QIAGEN Corp.
Valencia, CA). An RNase-free DNase (QIAGEN) was used to reduce genomic
DNA contamination. Quantitation of mRNA levels was performed using a two-
step real-time PCR method on a Bio-Rad Icycler (Bio-Rad). Approximately
1,000 ng of total RNA was reverse transcribed to cDNA using random hexamers
and Moloney murine leukemia virus reverse transcriptase (Applied Biosystems,
Foster City, CA) and then used to determine mRNA levels of -actin, c-myc,
N-myc, and REST in separate reactions. Each unknown was run at least three
times, and expression values were generated with Icycler software from a stan-
dard curve created using 0.1 to 50 ng of cDNA from the medulloblastoma cell
line D283 (American Type Culture Collection). All values were then normalized
to -actin content in the cDNA sample and are shown as means with standard
error. -Actin and c-myc levels were determined using commercially available
Taqman primers and probes (Applied Biosystems). The sequences of the for-
ward and reverse REST primers used for SYBR green quantitative PCR are
5-GAGGAGGAGGGCTGTTTACC-3 and 5-TCACAGCAGCTGCCATTT
AC-3, respectively. For N-myc, the forward and reverse primers were 5-TGA
AGAGGAAGATGAAGAGGAAGA-3 and 5-GTGACAGCCTTGGTGTTG
GA-3, respectively. Single melt peaks were obtained from both REST and
N-myc SYBR green primer pairs, and sequence analysis confirmed the identity of
the products. Statistical analysis of the correlation (Spearman test) and categor-
ical association (two-sided Fisher’s exact test) between c-Myc and REST was
performed using GraphPAD PRISM4 (GraphPAD Software, San Diego, CA).
Plasmids and stable transfection. The NheI/XhoI fragment of pcDNA3.1-
REST (28) was subcloned into the NheI/XhoI-digested plasmid pBig2r (62). The
clone obtained was confirmed by sequencing the junction region. The mouse
multipotent C17.2 (NSC-M) cells were derived from neonatal mouse cerebellum
transduced with v-Myc. Because v-Myc represents the activated form of the
c-Myc oncogene (38), these cells provide an excellent system for our experiments
(60). Construction and characterization of stable clonal cell lines NSC-M-V and
NSC-M-R were performed as described previously (63).
Cell culture conditions. NSC-M cells were cultured at 5% CO2, at 37°C, in
either proliferation medium (Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum, 5% horse serum, and 2 mM glutamine, and antibiotics/
antimycotics [all from Gibco]) or differentiation medium (Neurobasal medium
plus B27, antibiotics/antimycotics, and 2 mM glutamine [all from Gibco], plus
nerve growth factor [Chemicon], at a final concentration of 200 ng/ml). For
NSC-M-V or NSC-M-R stable clonal cells, the media were supplemented with
200 g/ml hygromycin (Roche) to maintain the presence of the transgene and,
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when needed, 20 g/ml doxycycline (Sigma) to repress the human REST trans-
gene expression. NSC-M, NSC-M-V, and NSC-M-R cells were propagated in
proliferation medium on uncoated tissue culture dishes. For the assay of cell
proliferation or differentiation, the cells were seeded on polylysine (Sigma)- and
laminin (Invitrogen)-coated dishes in the presence of proliferation medium.
Once the cells attached to the dish (approximately 2 h), they were processed
either immediately (proliferation condition, day 0) or at different time points
after the medium was replaced by differentiation medium (differentiation con-
ditions, day 2, 4, or 6).
RT-PCR assay. The RNeasy kit from QIAGEN was used to prepare total
RNA from the cells. RNAs were quantitated spectrophotometrically, and 200 ng
of total RNA was used for each sample to detect REST/NRSF in the RT-PCR
analysis. Primers used in these reactions had the following sequences: mActin F
57–76, 5-GTCCACACCCGCCACCAGTT-3; mActin R 816–841, 5-CGCTC
GTTGCCAATAGTGATGACCTG-3; hREST F 3311–3333, 5-TATCTTGAA
GAAGCAGCTCAAGG-3; hREST (bGH PolyA), 5-CAACTAGAAGGCAC
AGTCGAGG-3; mREST 2436–2455F, 5-GAGACAGCAAGCTTCTGAAG-
3; and mREST 2817-2792R, 5-CAGAGTATCTGTCTTCTGCTCAGTG-3.
An RT-PCR kit (QIAGEN) was used per the manufacturer’s instructions to
perform the initial reverse transcription. All three primer sets for actin, hREST,
and mREST were used in the same tube at the time of reaction. The cDNA was
amplified for 20 or 25 cycles under the following conditions: melting at 94°C for
1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min. The PCR
products were separated by electrophoresis on a 2.0% agarose gel at 80 V for
1.5 h.
Reporter gene assays. The REST-dependent promoter repression was deter-
mined in NSC-M, NSC-M-V, and NSC-M-R cells growing either in proliferation
medium (day 0) or in differentiation medium for 4 days (day 4) by transfection
with reporter plasmids pNaCh (RE) and pNaCh (RE). Transfected cells
were further incubated for 24 h in the same medium, and the assay was per-
formed as described previously (28, 37). The plasmid pSTluc was used as an
internal control (37, 53). The average chloramphenicol acetyltransferase (CAT)
activities from three experiments, which were normalized to luciferase activity,
were calculated as the percentage of REST activity: 100  [100  pNaCh
(RE)/pNaCh (RE)], where the REST activity for NSC-M at day 0 was taken
as 100%.
Immunofluorescence assay. Immunofluorescence assay experiments were per-
formed as described previously (63, 65). We used the following antibodies:
anti-VP16 (1:100) (Clontech), anti-unique -tubulin (1:500) (Tuj1; Covance Re-
search Products), anti-MAP2 (1:1,000, HM-2; Sigma), anti-synaptophysin I (1:
200, mab368; Chemicon), anti-glial fibrillary acidic protein (anti-GFAP; 1:500;
DAKO), horseradish peroxidase-conjugated anti-mouse or anti-rabbit immuno-
globulin G (IgG; HL, 1:20,000; Amersham), and Cy3-labeled anti-mouse or
anti-rabbit IgG (HL, 1:1,000; Amersham). A Leica epifluorescence microscope
was used to examine the staining of cells. Further analysis was carried out using
Metamorph software.
Cell proliferation assay. The cells growing either in proliferation medium (day
0) or in differentiation medium for various time points (day 2 or 4) were incu-
bated with 10 M bromodeoxyuridine (BrdU; Sigma) and were then washed
twice with 1 PBS and fixed with 10% buffered formalin for 20 min at room
temperature. The immunofluorescence of BrdU-labeled cells was elicited by first
blocking the cells with blocking buffer (1 PBS containing 10% normal goat
serum, 10% powdered dry milk, and 0.2% Triton X-100) for 1 h at room
temperature. The blocking buffer was removed, and the cells were incubated with
1 PBS containing mouse anti-BrdU antibody (containing nucleases) (Roche) at
a dilution of 1:15 for 1 h at 37°C. The cells were washed three times for 5 min
each with 1 PBS with gentle agitation. This was followed by incubation with
Cy3-conjugated goat anti-mouse antibodies (Amersham) at a dilution of 1:1,000
for 1 h at 37°C. The cells were washed three times with 1 PBS with gentle
agitation and allowed to air dry. The stained cells were covered with slow-fade
antifade (Molecular Probes) containing 1 g/ml 4,6-diamidino-2-phenylindole
(DAPI; Molecular Probes). The cells were analyzed by immunofluorescence
assay as described above. The average values from five different fields were used
for each data point. Each experiment was repeated four times.
Western blotting assay. Cells were seeded at a density of 5  105 cells per
15-cm petri dish coated with 0.1 mg/ml polylysine and 0.1 mg/ml of laminin and
grown in 5 ml Neurobasal medium (GIBCO, Bethesda, MD) supplemented with
B27 and nerve growth factor (Chemicon) at a final concentration of 200 ng/ml
and incubated at 37°C and 5% CO2 tension. In some experiments, replication-
incompetent adenovirus expressing either green fluorescent protein (GFP) or
REST-VP16 (Ad.GFP and Ad.REST-VP16, respectively) was used to infect
these cells at a multiplicity of infection of 100 for 4 h. Cells were either imme-
diately harvested (day 0), or the volume of medium was then raised to 15 ml and
cells were incubated in the differentiation medium further for 3 days postinfec-
tion. Infection efficiency was determined by counting the number of GFP-posi-
tive cells and was found to be 50%. Cells, adenovirus infected or uninfected,
were harvested and lysed by addition of Laemmli buffer, and cell extracts were
subjected to Western blot analysis using mouse anti-PARP antibody (BD Pharm-
ingen) at a dilution of 1:500. The antibody recognizes an 85-kDa product from
mouse cells. In some experiments, anti-neuronal -tubulin (Tuj1, 1:500 dilution;
Covance) or anti--tubulin (1:500 dilution; Covance) was also used.
Intracranial inoculation of cells into mice and assay for tumor formation. The
intracranial inoculation of cells into nude mice was performed following “M. D.
Anderson Institutional Animal Care and Use Guidelines.” Cells (2  105 cells in
5 l of cell growth medium) were inoculated into groups of mice by using an
implantable guide-screw system we have described elsewhere (19, 35, 65). The
mice were sacrificed by CO2 inhalation 6 weeks later, and their brains were fixed
with formalin and embedded in paraffin; 4- to 5-m brain sections were exam-
ined in the same way as the human medulloblastoma brain specimens.
RESULTS
Many primary human medulloblastomas express both
REST/NRSF and c-Myc proteins. As described above, many
human medulloblastoma tumor specimens and cell lines have
been found to express c-Myc or REST/NRSF. However, be-
cause neither protein by itself can cause tumor formation, we
wondered whether human medulloblastoma tumor samples
expressed both Myc and REST/NRSF proteins. We used im-
munohistochemical analysis to examine 21 surgically excised,
formalin-fixed, paraffin-embedded tumor tissue specimens or-
ganized in a tissue array with anti-REST, anti-c-Myc, and anti-
N-Myc antibodies. The results are shown in Fig. 1 and sum-
marized in Table 1. As expected, normal cerebellar cortex
tissue was composed of granular cell neurons with uniform,
round nuclei and interspersed pale neuropil islands (glomer-
uli), whereas medulloblastoma tissue was composed of densely
packed cytologically atypical tumor cells with enlarged, irreg-
ular, hyperchromatic nuclei (Fig. 1). All six normal control
cerebellar tissues stained negatively for anti-REST/NRSF, an-
ti-c-Myc, and anti-N-Myc antibodies. However, 17 of 21 me-
dulloblastoma tumor samples stained positively for REST/
NRSF, with strong signals () in 6 and weak signals () in
11. The remaining four samples showed no REST/NRSF sig-
nal. In contrast, 14 of the 21 tumor samples stained positively
for c-Myc, with strong signals () in 9 and weak signals ()
in 5. The remaining five samples showed no c-Myc positivity.
Similarly, 16 of the 21 tumor samples stained positively for
N-Myc, with strong signals () in 6 and weak signals () in
10. The remaining seven samples showed no c-Myc positivity.
High-magnification (1,000) photomicrographs showed the
nuclear staining for REST, c-Myc, and N-Myc (Fig. 1). Thus,
whereas 52% samples showed coexpression of both N-Myc and
REST/NRSF proteins at various levels (11 of 21), strong sig-
nals for both c-Myc and REST/NRSF were observed in only
14% (3 of 21) of samples. Likewise, 48% of samples (10 of 21)
showed coexpression of REST/NRSF and N-Myc, with strong
signals in 14% (3 of 21) of samples. Finally, 48% of the samples
expressed REST/NRSF, c-Myc, and N-Myc proteins. It is
worth noting that in two cases on Table 1, REST and N-myc
are coexpressed in the absence of detectable c-Myc protein.
This suggested the possibility that either c- or N-Myc is capable
of cooperating with REST and was supported by our data
shown below (Fig. 2). Although double-labeling studies were
not performed, the fact that the majority of cells in a given
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tumor were immunopositive for both REST and Myc suggests
that the proteins were being coexpressed in individual nuclei.
To obtain more quantitative data, we used real-time RT-
PCR to investigate the association between REST and Myc
transcript levels. Expression was analyzed in mRNA extracted
from 40 snap-frozen primary medulloblastomas for which we
had previously measured c-Myc and N-Myc expression levels
(D. Stearns and C. G. Eberhart, unpublished data). REST was
detected in all samples, and many of the tumors with high REST
levels were also among those with elevated c-Myc expression
(Fig. 2). REST and c-Myc mRNA levels showed a statistically
significant positive correlation overall (Spearman r	 0.36; P	
0.02). However, several cases with high REST levels contained
relatively little c-Myc. We were curious whether N-myc might
substitute for c-Myc in these cases, as N-myc gene amplifica-
tion has also been associated with aggressive medulloblastoma
biology (16). Interestingly, four cases with high REST and low
c-Myc had above-median levels of N-Myc (Fig. 2, inset). Thus,
high-level REST expression appears to be commonly associ-
ated with elevated expression of one of these two myc onco-
genes. As a final measure of the association between c-Myc
and REST, we used Fisher’s exact test to determine whether
tumors with very high (top third) REST expression also had
very high (top third) c-Myc expression. The combined high-
FIG. 1. Primary human medulloblastoma specimens coexpress REST/NRSF and c-Myc proteins. Paraffin-embedded medulloblastoma tissue
and normal brain tissue adjacent to the tumor were processed; stained with H&E, anti-REST/NRSF antibody (-REST), anti-c-Myc antibody
(-c-Myc), or anti-N-Myc antibody (-N-Myc); analyzed as described in Materials and Methods; and photographed under a light microscope.
Magnifications of 400 and 1,000 are shown.
TABLE 1. Status of immunoreactivity in medulloblastoma
patient samples
Age (yr)
Result fora:
REST/NRSF c-Myc N-Myc
22   
2   
9   
25   
34   
8   
4   
20   
15   
2   
12   
26   
11   
2   
2   
26   
20   
3   
10   
11   
7   
a , negative; , moderately positive; , strongly positive.
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REST/high-c-Myc category (33%) was significantly more com-
mon than would be predicted by chance association (P	 0.04),
supporting the concept that these genes might act together in
medulloblastoma pathogenesis.
Construction of NSC clones stably expressing Myc and
doxycycline-regulated human REST/NRSF transgene. We
used cerebellum-derived, neonatal mouse brain NSCs stably
expressing an activated form of c-Myc (NSC-M cells) to further
study the functional roles of Myc and REST in medulloblas-
toma tumorigenesis (60, 61). We generated stable clonal cells
expressing either the vector (NSC-M-V cells) or human REST
transgene (NSC-M-R cells) by using the bidirectional doxycy-
cline-regulated pBig2r vector system by a method we described
previously (63, 65). Selected clones were assayed using PCR to
verify the appropriate clonal cells (data not shown). The
pBig2r construct efficiently expressed the encoded transgene in
the absence of doxycycline (Dox), and the cells of the clonal
cell line NSC-M-R stably expressed high levels of the human
REST transgene mRNA when grown without doxycycline
(Dox) (data not shown). As expected for normal NSCs (2, 3),
NSC-M cells and NSC-M-V cells expressed the endogenous
mouse REST (mREST) transcripts only under proliferation
conditions (d0), and the expression ceased upon neuronal dif-
ferentiation (d2, d4, and d6) as assayed by RT-PCR (Fig. 3A).
NSC-M-R cells followed the same expression pattern for
mREST but, in contrast, expressed the human REST trans-
gene (hREST) under both proliferation and differentiation
conditions (Fig. 3A).
To confirm that the expression pattern of REST/NRSF tran-
script levels during neuronal differentiation shown in Fig. 3A
was also reflected in its transcriptional repression activity, we
used a reporter gene system that is well established to detect
REST/NRSF-specific activity in the cell (11, 28, 37, 65). The
system involves comparison of reporter gene activities from
two plasmids. The first, pNaCh (RE), contains the bacterial
CAT reporter gene under the control of sodium channel type
II promoter/enhancer (NaCh) elements. NaCh elements are
mammalian native neuronal promoter/enhancer sequences
that contain the REST/NRSF binding site (RE) and are
acted on by functional REST/NRSF. The second reporter plas-
mid, pNaCh (RE), contains the CAT reporter gene under
the control of the “minimal” NaCh elements without the RE1
sequence (RE). Functional REST/NRSF does not repress
the promoter activity of this plasmid. Thus, when functional
REST/NRSF is present in the cell, the CAT activity generated
from pNaCh (RE) is lower than that from pNaCh (RE)
because REST/NRSF causes promoter repression from
pNaCh (RE), and not pNaCh (RE).
The NSC-M and NSC-M-V cells, grown under either cycling
conditions (day 0) or differentiation conditions (day 4), were
transiently cotransfected with the reporter plasmid pNaCh
(RE) or pNaCh (RE) and an internal control plasmid,
pSTluc, which contains the luciferase reporter gene under the
control of an Sp1-containing basic promoter (36, 43). The
average CAT activities from three experiments, which were
normalized to luciferase activity, were rendered as the percent-
age of REST activity, as described in Materials and Methods.
As shown in Fig. 3B, whereas undifferentiated cycling NSC-M
and NSC-M-V cells grown with or without doxycycline showed
high levels of REST/NRSF activity (day 0), the differentiation
FIG. 2. Coexpression of REST/NRSF and c-Myc mRNA. Quantitative RT-PCR was used to analyze mRNA levels of REST/NRSF and c-Myc
in 40 snap-frozen primary human medulloblastomas. Each tumor is represented by a bar, and they are ordered on the x axis from highest to lowest
level of c-Myc mRNA expression after normalization to actin. This highlights the elevated REST/NRSF levels in many of the cases with high c-Myc.
Interestingly, several of the tumors with elevated REST/NRSF but low c-Myc levels (arrows) had elevated (above median) N-Myc mRNA levels.
The inset shows a scatter plot of N-Myc levels for all 40 cases, with the 4 cases marked with arrows circled.
1670 SU ET AL. MOL. CELL. BIOL.
conditions (day 4) resulted in severely reduced REST/NRSF
activity, indicating that REST/NRSF activity is lost during the
neuronal differentiation of NSCs.
When NSC-M-R cells were cultured with doxycycline (Fig.
3B), they showed a pattern of REST/NRSF activity similar to
that of NSC-M and NSC-M-V cells; that is, activity was high in
cycling cells (day 0) and diminished in differentiating cells (day
4). In contrast, when NSC-M-R cells were cultured without
doxycycline, they showed higher REST/NRSF activity than did
NSC-M cells and NSC-M-Vcells under cycling conditions (day
0) and continued showing high REST activity under differen-
tiation conditions (day 4), suggesting that the human REST
transgene was responsible for the continued REST activity in
these cells (Fig. 3B). Thus, whereas all cells expressed REST/
NRSF activity under proliferation conditions, only the NSC-
M-R cells (Dox) expressed the REST/NRSF activity under
differentiation conditions.
Forced expression of REST/NRSF in NSCs blocks neuronal
differentiation. To determine the effect of continued REST/
NRSF expression in NSC-M-R cells during neuronal differen-
tiation (day 4), we examined whether the terminal neuronal
differentiation markers neuronal -tubulin and MAP2 were
expressed in clonal cells growing under differentiation condi-
tions with and without doxycycline. As shown in Fig. 4, the
NSC-M-V cells, like the NSC-M cells, expressed both markers
irrespective of whether they were cultured with or without
doxycycline. NSC-M-R cells cultured with doxycycline also ex-
pressed these markers. In contrast, NSC-M-R cells cultured
without doxycycline did not express either marker (Fig. 4). The
pattern of expression of other neuronal differentiation genes,
synapsin and secretogranin II, was similar (data not shown).
Another REST/NRSF clone, NSC-M-R, behaved very simi-
larly to the NSC-M-R cells in all our experiments (data not
shown), indicating that the effect of REST/NRSF was indepen-
dent of its genomic integration site. Taken together, these
results indicate that proliferating NSCs normally express en-
dogenous REST/NRSF, but its activity is rapidly blocked as the
cells enter neuronal differentiation. These cells then become
mature neurons. In contrast, NSC-M-R cells continue to ex-
press REST/NRSF as they enter neuronal differentiation and,
as a result, cannot become terminally differentiated neurons.
REST/NRSF-mediated blockade of neuronal differentiation
confers a proliferation advantage in vitro. Because forced ex-
pression of REST/NRSF in NSCs blocked neuronal differen-
tiation, to determine whether expression of REST/NRSF in
NSC-M-R cells also confers a proliferative advantage, we mea-
sured BrdU incorporation into NSC-M cells and NSC-M-R
cells under in vitro conditions during cycling (day 0) and dif-
ferentiation (days 2 and 4). By culturing the cells either with or
without doxycycline in the medium, we also performed these
experiments in the presence and absence of exogenously ex-
pressed REST/NRSF. Figure 5A shows the results of the im-
munocytochemical assay for BrdU uptake, and Fig. 5B shows
the percentages of BrdU-positive cells. As expected, the rate of
BrdU incorporation into NSC-M cells, cultured either with or
without doxycycline, decreased drastically as they differenti-
ated. The rate at which BrdU was incorporated into NSC-M-R
cells assumed the same pattern when the expression of the
FIG. 3. Endogenous REST/NRSF is expressed in proliferating NSCs and the expression is repressed as the NSCs enter neuronal differentiation.
(A) Endogenous mouse REST/NRSF (mREST) and transgenic human REST/NRSF (hREST) transcription was assessed by RT-PCR in
NSC-M-R, NSC-M-V, and NSC-M cells growing in proliferation medium (day 0) or in differentiation medium in vitro for 2, 4, and 6 days. Actin
transcripts were measured as an internal control. (B) The percentage of REST transcriptional repression activity was determined in NSC-M,
NSC-M-V, and NSC-M-R cells growing in proliferation medium (day 0) or differentiation medium for 4 days (day 4). The cells were cultured either
with (D) or without (D) doxycycline, transfected with the reporter plasmid pNaCh (RE) or pNaCh (RE), and analyzed as described in the
text. The data represent percent REST activity.
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exogenous REST/NRSF was prevented by culturing the cells
with doxycycline. In contrast, the rate at which BrdU was
incorporated into NSC-M-R cells remained high when the
expression of the exogenous REST/NRSF was kept steady by
culturing the cells without doxycycline. Thus, although c-Myc is
known to cause neuronal progenitor cell proliferation, these
experiments indicated that, by blocking differentiation, the ad-
ditional REST/NRSF expression conferred an enormous pro-
liferative advantage on NSC-M-R cells compared with NSC-M
and NSC-M-V cells, but only when they traveled down the
neuronal differentiation pathway.
REST/NRSF-mediated blockade of neuronal differentiation
in vivo causes tumors in the cerebellum, but not in the cerebral
cortex. Because the cerebellum is the major site of medullo-
blastoma tumorigenesis (31, 52), we wanted to determine the
properties of NSC-M-R cells in mouse cerebellum. We in-
jected NSC-M, NSC-M-V, or NSC-M-R cells into the cerebel-
lums of nude mice (10 mice per group). We sacrificed the mice
6 weeks later and performed histological analysis of their par-
affin-embedded brains. As shown in Fig. 6 and 7, the NSC-M
and NSC-M-V cells injected into the cerebellum integrated
into the cerebellum within about 4 weeks in a nontumorigenic,
cytoarchitecturally appropriate manner (10 out of 10 mice for
both NSC-M and NSC-M-V cells). Histological analysis of the
brains of these mice showed that they had a normal cerebellar
architecture with an appropriate vermian histological morphol-
ogy, including normal molecular, Purkinje cell, and granule cell
layers, with granule cell neurons showing the characteristic
monotonous, regular, round nuclei. In contrast, large cerebel-
lar tumors with irregular, pleomorphic, and hyperchromatic
nuclei developed in mice inoculated with NSC-M-R cells (8 out
of 10 mice), and these tumors were morphologically similar to
human medulloblastomas (see Fig. 1). In most cases, the ver-
mian cerebellar cortex, including the granule cell layer, was
compressed as a result of tumor expansion. Thus, NSCs that
overexpressed activated c-Myc alone (NSC-M and NSC-M-V
cells) did not produce cerebellar tumors in mice but did pro-
duce tumors when they also overexpressed REST/NRSF, indi-
cating that the overexpression of both activated c-Myc and
REST/NRSF in NSCs produces cerebellar tumors.
To determine whether tumor formation is location specific,
we injected NSC-M, NSC-M-V, or NSC-M-R cells into the
cerebral cortex of nude mice as described above. As shown in
Fig. 6, none of the cells formed tumors, suggesting that the
cerebellar environment facilitates c-Myc-REST/NRSF-medi-
ated tumor formation.
REST/NRSF-mediated cerebellar tumors are blocked from
terminal neuronal differentiation. To confirm that the cells
that made up the cerebellar tumors produced by NSC-M-R
cells were also blocked from terminal neuronal differentiation,
we examined the immunohistochemical expression of the dif-
ferentiation marker MAP2 in paraffin-embedded sections. As
shown in Fig. 8, NSC-M-V specimens produced MAP2 at lev-
els indistinguishable from those of background brain struc-
tures. In contrast, NSC-M-R tumors did not produce any
MAP2. These results indicate that the abnormal expression of
REST/NRSF in these tumors prevented the cells from under-
going terminal neuronal differentiation.
The gene encoding synaptophysin, another marker of termi-
nal neuronal differentiation, is also a direct target of REST/
NRSF (63, 65). To further confirm that the tumor-producing
cells are blocked from terminal neuronal differentiation and do
not express REST/NRSF target genes, we examined paraffin-
embedded sections for immunohistochemical expression of
synaptophysin (SYP). NSC-M-V cells produced synaptophysin
at levels indistinguishable from those of background brain
structures, similar to MAP2 staining (data not shown). In con-
trast, whereas the surrounding granular cell neurons with reg-
ular round nuclei expressed synaptophysin, the tumor cells
with irregular, pleomorphic nuclei did not, indicating that
these cells do not express REST/NRSF target genes and did
not undergo terminal neuronal differentiation.
To confirm that the tumor-producing cells did not differen-
tiate in the glial pathway, we examined the expression of
GFAP in paraffin-embedded sections with anti-GFAP antibod-
FIG. 4. Forced expression of REST/NRSF in NSCs blocks neuro-
nal differentiation. NSC-M, NSC-M-V, and NSC-M-R cells were cul-
tured with (Dox) or without (Dox) doxycycline under neuronal
differentiation conditions for 4 days, and their level of neuronal dif-
ferentiation was determined in an immunofluorescence analysis in
which anti-neuronal -tubulin (Tuj1) and anti-MAP2 antibodies were
used.
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ies. NSC-M-V cells did not show any difference in GFAP
staining from those of background brain structures (data not
shown). As shown in Fig. 8, strong cytoplasmic reactivity for
GFAP was seen in astrocytes but the tumor cells did not
express GFAP, suggesting that NSC-M-R cells did not undergo
glial differentiation.
Countering REST/NRSF function blocks tumorigenicity.
Previously we found that REST-VP16 counters the effects of
endogenous REST/NRSF in human medulloblastoma cells
overexpressing REST/NRSF, induces apoptosis, and counter-
acts the cells’ tumorigenicity (19, 37). To determine whether
the NSC-M-R cells respond to REST-VP16 in the same fash-
ion, we infected NSC-M-R cells grown in the absence of doxy-
cycline in vitro with Ad.GFP (control) and Ad.REST-VP16 at
a multiplicity of infection of 100. We then looked for the active
apoptosis of these cells on the basis of the detection of the
anti-PARP antibody, which recognizes only the cleaved form
of PARP. As shown in Fig. 9A, REST-VP16 specifically caused
FIG. 5. REST/NRSF-mediated neuronal differentiation block confers a proliferation advantage in vitro. The amount of BrdU incorporation
was determined by immunocytochemical analysis (A) and was represented as the percentage of cells (NSC-M or NSC-M-R) showing BrdU labeling
(B) growing in proliferation medium (d0) or differentiation medium for day 2 (d2) or day 4 (d4) with (Dox) or without (Dox), as described
in the text.
FIG. 6. REST/NRSF-mediated neuronal differentiation block causes tumors in the cerebellums but not cerebral cortex of mice. NSC-M,
NSC-M-R, and NSC-M-R (a second clone of NSC-M-R) cells were injected into the cerebellums and cerebral cortex of mice. The mice were
sacrificed 6 weeks later, and their paraffin-embedded brain sections were histologically analyzed. Only the NSC-M-R and NSC-M-R cells produced
cerebellar tumors (arrows).
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high levels of apoptosis in NSC-M-R cells but not in NSC-M or
NSC-M-V cells. Thus, these experiments showed that NSC-
M-R cells followed the same fate in vitro in response to REST-
VP16 as human medulloblastoma cells do.
We then inoculated REST-VP16-infected NSC-M-R cells
into the cerebellums of mice, sacrificed the mice 6 weeks later,
and examined paraffin-embedded sections of their brains. As
shown in Fig. 9B, Ad.REST-VP16, but not Ad.GFP, blocked
the tumorigenicity of NSC-M-R cells, indicating that, similar to
human REST/NRSF-containing human medulloblastoma
cells, countering REST/NRSF in NSC-M-R cells can eliminate
their cerebellar tumorigenic potential.
The mechanism of REST-VP16-mediated induction of apo-
ptosis in human medulloblastoma cells (19, 37) and NSC-M-R
cells is unknown. One possible mechanism is the persistent
presence of the opposing REST/NRSF and REST-VP16 activ-
ities in these cells, leading to the generation of conflicting
signals of stem cell properties and differentiation properties,
respectively. To confirm that REST-VP16-mediated apoptosis
in NSC-M-R cells is caused by REST-VP16 activity and not by
abnormal production of toxic levels of the protein, we exam-
ined the expression of the REST-VP16 target gene neuronal
-tubulin in these cells by performing an immunofluorescence
assay. Although neither NSC-M nor NSC-M-R cells produced
neuronal -tubulin when infected with Ad.GFP (data not
shown), they did produce it when infected with Ad.REST-
VP16 (Fig. 9C). To further confirm this observation, we inves-
tigated the expression of neuronal -tubulin in NSC-M and
NSC-M-R cells, uninfected or infected with Ad.REST-VP16,
by performing the Western blotting assay. As shown in Fig. 9D,
only the Ad.REST-VP16-infected cells showed the expression
of neuronal -tubulin. These results indicate that REST-VP16
expressed in NSC-M and NSC-M-R cells as a result of adeno-
viral infection produced functionally active protein.
DISCUSSION
Our results indicate that many human medulloblastomas
coexpress abnormally high levels of Myc and REST/NRSF. We
also observed that NSCs overexpressing activated Myc and
REST/NRSF proteins are blocked in neuronal differentiation
and give rise to cerebellar tumors morphologically similar to
human medulloblastoma. These cells did not produce tumors
in the cortex, indicating a role of the local brain environment
in formation of the tumors. Although the environmental dif-
ference between the cerebellum and the cortex very likely is
because of the difference in trophic factors, the exact nature of
such factors is not yet known. We further found that counter-
ing the effects of REST/NRSF in NSC-M-R cells caused apo-
ptosis and counteracted the tumorigenic potential of the cells.
On the basis of these findings, we propose a model in which
efficient medulloblastoma tumorigenesis occurs when two con-
ditions occur in NSCs: overall increased proliferation as a
result of Myc expression and lack of differentiation (mainte-
nance of “stemness”) as a result of REST/NRSF expression
(Fig. 10).
FIG. 7. Morphological details of cerebellar tumors. Detailed histological analysis of paraffin-embedded brain sections of mice injected with
VP16-tagged NSC-M-R cells show tumor cells with irregular, pleomorphic, and hyperchromatic nuclei. Immunohistochemistry studies show these
cells are also positive for VP16. The paraffin-embedded brain sections of mice injected with control VP16-tagged NSC-M-V cells show normal
granule cell neurons with regular, round nuclei. VP16-positive cells cannot be detected in these sections.
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Normally, when NSCs are signaled to travel down the neu-
ronal differentiation pathway, they rapidly stop transcribing the
REST/NRSF gene. Because the REST/NRSF protein is no
longer present to block its target terminal differentiation
genes, the cells can successfully differentiate into neurons. In
medulloblastoma, the Myc and REST/NRSF proteins are ab-
normally overexpressed. When NSCs are induced to prolifer-
ate rapidly by Myc, then travel down the neuronal differenti-
ation pathway, the deregulated REST/NRSF expression
cannot be extinguished, leading to an ongoing block of neuro-
nal differentiation. These still-dividing cells abnormally accu-
mulate, thereby initiating medulloblastoma formation.
Our hypothesis is not at odds with the possibility that tumor
maintenance and progression then result from the deregula-
tion of other genes, caused by the abnormal physiology of the
tumor cells. This hypothesis of tumor formation resulting from
the capture of dividing cells at a stage before full differentia-
tion may be a new paradigm explaining the initiation of tumors
believed to originate from and resemble undifferentiated or
partially differentiated cells, such as medulloblastomas, neuro-
blastomas, and rhabdomyosarcomas (48). Indeed, such tumors
usually occur in children and adolescents, in whom differenti-
ation pathways are probably more active than they are in
adults.
Our model of efficient medulloblastoma formation from
NSCs as the result of the cooperation of both proliferation
advantage and differentiation-block is not at odds with the
less-efficient medulloblastoma formation that occurs in the
presence of only one of these steps. For example, activation of
the Shh pathway as the result of a PTCH gene mutation, which
FIG. 8. REST/NRSF-mediated cerebellar tumors are blocked in neuronal differentiation. The paraffin-embedded brain sections of mice
injected with NSC-M-R and control NSC-M-V cells were analyzed in immunohistochemistry studies to determine the expression of the neuronal
differentiation markers MAP2 and synaptophysin (SYP) and glial differentiation marker GFAP. NSC-M-R cells were negative for synaptophysin,
MAP2, and GFAP.
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increases NSC proliferation, is known to occur in approxi-
mately 10% of medulloblastoma patients (50, 66). The severity
of this disease can be enhanced by addition of c-Myc, another
factor promoting NSC proliferation (52). Thus, it is conceiv-
able that medulloblastomas develop as a result of a factor or
factors favoring either the proliferation step or the differenti-
ation-block step but that additional factors reinforcing the
same step and/or the other step augment tumorigenesis.
Previously, we found that many human medulloblastoma
cell lines and human medulloblastoma patient samples abnor-
mally overexpress REST/NRSF as compared with neuronal
cells or normal brain cells (19, 37). As expected, the REST/
NRSF-positive tumor cells do not express the REST/NRSF
target genes, such as synapsin, which, in turn, can be expressed
by REST-VP16 (19, 37). That the overexpression of REST/
NRSF plays such an oncogenic role in neuronal cells is further
supported by studies from other laboratories indicating over-
expression of REST/NRSF in several neuroblastoma cells with
concomitant repression of neuronal differentiation genes (27,
46). Furthermore, when the neuroblastoma cells were forced
to differentiate, they showed a decrease in REST/NRSF ex-
pression and an increase in neuronal markers. These studies
suggested that the abnormal overexpression of REST/NRSF in
neuronal cells, in which REST/NRSF is normally not present,
blocks these cells from terminal neuronal differentiation and
produces the cancerous phenotype, perhaps by forcing the cells
to persist in a stem/progenitor state.
In contrast, several studies also showed that whereas normal
bronchial epithelium expressed REST/NRSF activity, several
established small cell lung cancer cell lines as well as primary
samples showed reduced REST/NRSF activity with concomi-
tant abnormal expression of REST/NRSF target genes, such as
the glycine receptor 1 subunit or vasopressin (12, 25, 45).
Such a tumor-suppressor function of REST/NRSF was also
seen in colorectal cancers (47, 67). These studies suggested
that the abnormal lack of REST/NRSF activity in lung and
colon epithelial cells, which normally express REST/NRSF and
repress expression of neuronal genes, leads to oncogenic con-
version of these cells, perhaps by aberrant expression of REST/
NRSF target genes resulting in the abnormal neuroendocrine
phenotype sometimes observed in these tumors. Thus, REST
may have both tumorigenic and tumor-suppressor effects, de-
FIG. 9. Countering REST/NRSF function blocks cerebellar tumorigenicity. (A) Cell extracts prepared from Ad.GFP (G)- or Ad.REST-VP16
(RV)-infected NSC-M, NSC-M-V, and NSC-M-R cells were subjected to Western blot analysis in which antibodies were used that detect cleaved
PARP (85 kDa) and -tubulin (55 kDa). (B) NSC-M-R cells infected with Ad.GFP or Ad.REST-VP16 were inoculated into the mouse cerebellum.
The mice were sacrificed 6 weeks later, and their paraffin-embedded brain sections were histologically analyzed. The tumor produced by NSC-M-R
cells infected with Ad.GFP is indicated by arrows. (C) NSC-M and NSC-M-R cells infected with Ad.REST-VP16 were examined by immunoflu-
orescence using anti-neuronal -tubulin (red). The cell nuclei were also labeled with DAPI (blue). (D) NSC-M and NSC-M-R cells, uninfected
() or infected () with Ad.REST-VP16, were examined by Western blotting analysis using anti-neuronal -tubulin. Anti--tubulin was used as
an internal control.
FIG. 10. A model for medulloblastoma tumorigensis triggered by
the transcriptional repressor REST/NRSF and Myc. Please see the text
for details.
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pending on the cell type, which would indicate that REST is a
major biological regulator of normal and abnormal develop-
ment.
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